These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35383578)

  • 1. Fluvoxamine in Nonhospitalized Patients With Acute COVID-19 Infection and the Lack of Efficacy in Reducing Rates of Hospitalization, Mechanical Ventilation, and Mortality in Placebo-Controlled Trials: A Systematic Review and Meta-Analysis.
    Bhuta S; Khokher W; Kesireddy N; Iftikhar S; Beran A; Mhanna M; Patel NJ; Patel M; Burmeister C; Assaly R
    Am J Ther; 2022 May-Jun 01; 29(3):e298-e304. PubMed ID: 35383578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: A systematic review and meta-analysis.
    Lu LC; Chao CM; Chang SP; Lan SH; Lai CC
    J Infect Public Health; 2022 Nov; 15(11):1259-1264. PubMed ID: 36272390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ivermectin for preventing and treating COVID-19.
    Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of fluvoxamine in patients with COVID-19: A systematic review and meta-analysis from randomized controlled trials.
    Zhou Q; Zhao G; Pan Y; Zhang Y; Ni Y
    PLoS One; 2024; 19(5):e0300512. PubMed ID: 38753761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis.
    Lee TC; Vigod S; Bortolussi-Courval É; Hanula R; Boulware DR; Lenze EJ; Reiersen AM; McDonald EG
    JAMA Netw Open; 2022 Apr; 5(4):e226269. PubMed ID: 35385087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications.
    Prasanth MI; Wannigama DL; Reiersen AM; Thitilertdecha P; Prasansuklab A; Tencomnao T; Brimson S; Brimson JM
    Sci Rep; 2024 Jun; 14(1):13462. PubMed ID: 38862591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis.
    Wen W; Chen C; Tang J; Wang C; Zhou M; Cheng Y; Zhou X; Wu Q; Zhang X; Feng Z; Wang M; Mao Q
    Ann Med; 2022 Dec; 54(1):516-523. PubMed ID: 35118917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
    Bramante CT; Huling JD; Tignanelli CJ; Buse JB; Liebovitz DM; Nicklas JM; Cohen K; Puskarich MA; Belani HK; Proper JL; Siegel LK; Klatt NR; Odde DJ; Luke DG; Anderson B; Karger AB; Ingraham NE; Hartman KM; Rao V; Hagen AA; Patel B; Fenno SL; Avula N; Reddy NV; Erickson SM; Lindberg S; Fricton R; Lee S; Zaman A; Saveraid HG; Tordsen WJ; Pullen MF; Biros M; Sherwood NE; Thompson JL; Boulware DR; Murray TA;
    N Engl J Med; 2022 Aug; 387(7):599-610. PubMed ID: 36070710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.
    Reis G; Dos Santos Moreira-Silva EA; Silva DCM; Thabane L; Milagres AC; Ferreira TS; Dos Santos CVQ; de Souza Campos VH; Nogueira AMR; de Almeida APFG; Callegari ED; de Figueiredo Neto AD; Savassi LCM; Simplicio MIC; Ribeiro LB; Oliveira R; Harari O; Forrest JI; Ruton H; Sprague S; McKay P; Glushchenko AV; Rayner CR; Lenze EJ; Reiersen AM; Guyatt GH; Mills EJ;
    Lancet Glob Health; 2022 Jan; 10(1):e42-e51. PubMed ID: 34717820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can we still consider treatment with colchicine effective in SARS-COV-2 infection? Systematic review, meta-analysis, and trial sequential analysis.
    De-Miguel-Balsa E; Estevan-Ortega R; Sempere-Selva MT; Latour-Pérez J; Baeza-Román A; Moya-Martinez A; Ramos-Rincon JM
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7151-7161. PubMed ID: 34859881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Fluvoxamine as Outpatient Treatment for Patients With Covid-19: A Systematic Review and Meta-analysis of Clinical Trials.
    Vatvani AD; Kurniawan A; Hariyanto TI
    Ann Pharmacother; 2023 Dec; 57(12):1389-1397. PubMed ID: 37002592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.
    Lenze EJ; Mattar C; Zorumski CF; Stevens A; Schweiger J; Nicol GE; Miller JP; Yang L; Yingling M; Avidan MS; Reiersen AM
    JAMA; 2020 Dec; 324(22):2292-2300. PubMed ID: 33180097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.
    Facente SN; Reiersen AM; Lenze EJ; Boulware DR; Klausner JD
    Drugs; 2021 Dec; 81(18):2081-2089. PubMed ID: 34851510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating fluvoxamine for the outpatient treatment of COVID-19: A systematic review and meta-analysis.
    Deng J; Moskalyk M; Zuo QK; Garcia C; Abbas U; Ramaraju HB; Rayner D; Park YJ; Heybati K; Zhou F; Lohit S
    Rev Med Virol; 2024 Jan; 34(1):e2501. PubMed ID: 38148036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic corticosteroids for the treatment of COVID-19.
    Wagner C; Griesel M; Mikolajewska A; Mueller A; Nothacker M; Kley K; Metzendorf MI; Fischer AL; Kopp M; Stegemann M; Skoetz N; Fichtner F
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014963. PubMed ID: 34396514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trial Sequential Analysis and Updated Meta-Analysis of Fluvoxamine on Clinical Deterioration in Adult Patients with Symptomatic COVID-19 Infection.
    Yu CL; Carvalho AF; Thompson T; Tsai TC; Tseng PT; Hsu CW; Tu YK; Yang SN; Hsu TW; Yeh TC; Liang CS
    Int J Environ Res Public Health; 2023 Feb; 20(5):. PubMed ID: 36901099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
    Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study).
    Siripongboonsitti T; Ungtrakul T; Tawinprai K; Nimmol T; Buttakosa M; Sornsamdang G; Jarrusrojwuttikul T; Silapant P; Mahanonda N
    Int J Infect Dis; 2023 Sep; 134():211-219. PubMed ID: 37393041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.